Stay updated with breaking news from Celcuity Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib ...
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results ...
08.05.2023 - MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first ...
Gagnon Securities LLC decreased its holdings in Celcuity Inc. (NASDAQ:CELC – Get Rating) by 33.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,655 shares of the company’s stock after selling 26,998 shares during the period. Gagnon Securities LLC owned 0.35% […]